1. Mermel LA. Prevention of intravascular catheter-related infections. Ann Intern Med 2000; 132: 391-402.
2. Laurenzi L, Natoli S, Benedetti C, et al. Cutaneous bacterial colonization, modalities of chemotherapeutic infusion, and catheter-related bloodstream infection in totally implanted venous access devices. Support Care Cancer 2004; 12:805-9.
3. Pascual A. Pathogenesis of catheter-related infections: lessons for new designs. Clin Microbiol Infect 2002; 8:256-64.
4. NNIS System. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2003, issued August 2003. Am J Infect Control 2003; 31:481-981.
5. Mermel LA. Correction: catheter catheter-related blood stream infections. Ann Intern Med 2000; 133:395.
6. Mermel L. Defining intravascular catheter-related infections: a plea for uniformity. Nutrition 1997;13(suppl):2S-4S.
7. O’Grady NP, Alexander M, Dellinger EP, et al. Centers for Disease Control and Prevention. Guidelines for the prevention of intravascular catheter-related infections. MMWR 2002; 51:RR-10:1–34.
8. Mermel LA, Farr BM, Sherertz RJ, et al. Guidelines for the management of intravascular catheter-related infections. Clin Infect Dis 2001; 32:1249–1272.
9. Calandra T and Cohen J; for the International Sepsis Forum Definition of Infection in the ICU Consensus Conference. The International Sepsis Forum Consensus Conference on Definitions of Infection in the Intensive Care Unit. Crit Care Med 2005; 33:1538 –1548.
10. Blot F, Schmidt E, Nitenberg G, et al. Earlier positivity of central venous versus peripheral blood cultures is highly predictive of catheter related sepsis. J Clin Microbiol 1998; 36:105 9.
11. Merrer J, De Jonghe B, Golliot F, Lefrant JY, Raffy B, Barre E. Complications of femoral and subclavian venous catheterization in critically ill patients. JAMA 2001; 286:700–707.
12. Goetz AM, Wagener MM, Miller JM, Muder RR. Risk of infection due to central venous catheters: effect of site of placement and catheter type. Infect Control Hosp Epidemiol 1998; 19:842–845.
13. Collignon P, Soni N, Pearson I, Sorrell T, Woods P. Sepsis associated with central vein catheters in critically ill patients. Intensive Care Med 1988; 14:227–231.
14. Lorente L, Henry C, Martin MM, Jiménez A, Mora ML. Central venous catheter-related infection in a prospective and observational study of 2,595 catheters. Critical Care 2006; 9(6):R631-5.
15. Maki DG, Stolz SM, Wheeler S, Mermel LA. Prevention of central venous catheter–related bloodstream infection by use of an antiseptic impregnated catheter: a randomized, controlled controlled trial. Ann Intern Med 1997; 127:257–66.
16. McConnell SA, Gubbins PO, Anaissie EJ. Do antimicrobial-impregnated central venous catheters prevent catheter-related bloodstream infection? Clin Infect Dis 2003; 37:65–72.
17. Crnich CJ, Maki DG. Are antimicrobial-impregnated catheters effective? Don’t throw out the baby with the bathwater. Clin Infect Dis 2004; 38:1287–92.
18. McConnell SA, Gubbins PO, Anaissie EJ. Are antimicrobial-impregnated catheters effective? Replace the water and grab your washcloth, because we have a baby to wash. Clin Infect Dis. 2004 Dec 15; 39(12):1829-33.
19. Crnich CJ and Maki DG. When does repetition reach the point of exhaustion? Clin Infect Dis 2005; 41:681–5.
20. Maki DG, Ringer M, Alvarado CJ. Prospective randomized trial of povidone-iodine, alcohol, and chlorhexidine for prevention of infection associated with central venous and arterial catheters. Lancet 1991; 338:339–43.
21. Chaiyakunapruk N, Veenstra DL, Lipsky BA, Saint S. Chlorhexidine compared with povidone-iodine solution for vascular catheter-site care: a meta-analysis. Ann Intern Med 2002;136:792-801.
22. Warren DK, Zack JE, Mayfield JL, et al. The effect of an education program on the incidence of central venous catheter-associated bloodstream infection in a medical ICU. Chest 2004; 126:1612-8.
23. Coopersmith CM, Rebmann TL, Zack JE, et al. Effect of an education program on decreasing catheter-related bloodstream infections in the surgical intensive care unit. Crit Care Med 2002; 30:59–64.
24. CDC. Reduction in central line-associated bloodstream infection among patients in intensive care units-Pensylvania, April 2001-March 2005. MMWR 2005; 54:1014-16.
25. Berenholtz SM, Pronovost PJ, Lipsett PA, et al. Eliminating catheter-related bloodstream infection in the intensive care unit. Crit Care Med 2004; 22:2014-2020.
26. Two-Year Project Improves Patient Safety in Michigan Hospital ICUs; BCHS Among the Leaders. Available at http://www.bchealth.com/news/ImpICUPatSafety.shtml
Antimicrobial Use in the ICU
Philip S. Barie, MD, MBA, FCCM
Weill Medical College of Cornell University
New York, New York, USA
1. Bratzler DW, Houck PM, Richards C, et al. Use of antimicrobial prophylaxis for major surgery: baseline results from the National Surgical Infection Prevention Project. Arch Surg 2005;140:174-182.
2. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control 2004;32:470-485.
3. Dormann AJ, Wigginhaus B, Risius H, et al. Antibiotic prophylaxis in percutaneous endoscopic gastrostomy (PEG)-results from a prospective randomized multicenter trial. Z Gastroenterol 2000;38:229-234.
4. Rebuck JA, Murry KR, Rhoney DH, et al. Infection related to intracranial pressure monitors in adults: analysis of risk factors and antibiotic prophylaxis. J Neurol Neurosurg Psychiatry 2000;69:381-384.
5. Luchette FA, Barie PS, Oswanski MF, et al. Practice management guidelines for prophylactic antibiotic use in tube thoracostomy for traumatic hemopneumothorax: The EAST Practice Management Guidelines Work Group. Eastern Association for Trauma. J Trauma 2000;48:753-757.
6. Rutherford EJ, Skeete DA, Brasel KJ. Management of the patient with an open abdomen: techniques in temporary and definitive closure. Curr Probl Surg. 2004;41:815-876.
7. Manian FA, Meyer PL, Setzer J, Senkel D. Surgical site infections associated with methicillin-resistant Staphylococcus aureus: do postoperative factors play a role? Clin Infect Dis 2003;36:863-868.
8. Ratilal B, Costa J, Sampaio C. Antibiotic prophylaxis for preventing meningitis in patients with basilar skull fractures. Cochrane Database Syst Rev 2006; (1):CD004884.
9. Villalobos T, Arango C, Kubilis P, Rathore M. Antibiotic prophylaxis after basilar skull fractures: a meta-analysis. Clin Infect Dis 1998;27:364-369.
10. Gosselin RA, Roberts I, Gillespie WJ. Antibiotics for preventing infection in open limb fractures. Cochrane Database Syst Rev 2004:(1):CD003764.
11. Gillespie WJ, Walenkamp G. Antibiotic prophylaxis of surgery for proximal femoral and other closed long bone fractures. Cochrane Database Syst Rev 2001;(1):CD000244.
12. Bozorgzadeh A, Pizzi WF, Barie PS, et al. The duration of antibiotic administration in penetrating abdominal trauma. Am J Surg 1999 ;177:125-131.
13. Fukatsu K, Saito H, Matsuda T, et al. Influences of type and duration of antimicrobial prophylaxis on an outbreak of methicillin-resistant Staphylococcus aureus and on the incidence of wound infection. Arch Surg 1997;132:1320-1325.
14. Namias N, Harvill S, Ball S, et al. Cost and morbidity associated with antibiotic prophylaxis in the ICU. J Am Coll Surg 1999;188:225-230.
15. Liberati A, D’Amico R, Pifferi S, Telaro E. Antibiotic prophylaxis in intensive care units: Meta-analyses versus clinical practice. Intensive Care Med 2000;26(Suppl 1):S38-S44.
16. Kreisel D, Savel TG, Silver AL, Cunningham JD. Surgical antibiotic prophylaxis and Clostridium difficile toxin positivity. Arch Surg 1995;130:989-993.
17, Shah T, Lai WK, Gow P, Leeming J, Mutimer D. Low-dose amphotericin for prevention of serious fungal infection following liver transplantation. Transpl Infect Dis 2005;7:126-132.
18. Pelz RK, Hendrix CW, Swoboda SM, et al. Double-blind placebo-controlled trial of fluconazole to prevent candidal infections in critically ill surgical patients. Ann Surg 2001;233:542-548.
19. Gleason TG, May AK, Caparelli D, et al. Emerging evidence of selection of fluconazole-tolerant fungi in surgical intensive care units. Arch Surg 1997;132:1197-201
20. Barie PS. Surf’s up at evidence beach. Surg Infect 2004;5:227-228 (Editorial).
21. Soares-Weiser K, Brezis M, Tur-Kaspa R, et al. Antibiotic prophylaxis of bacterial infections in cirrhotic inpatients: A meta-analysis of randomized controlled trials. Scand J Gastroenterol 2003; 38:193-200.
Therapy for Influenza: Present and Future
Henry Masur, MD, FCCM
National Institutes of Health
Washington, D.C., USA
1. Gaydos JC, Top FH, Hodder RA, Russell PK. Swine influenza A outbreak, Fort Dix, New Jersey, 1976. Emerg Infect Dis [serial on the Internet]. 2006 Jan Available at http://www.cdc.gov/ncidod/EID/vol12no01/05-0965.htm
2. Jefferson T, Demicheli V, Rivetti D, Jones M, Di Pietrantonj C, Rivetti A. Antivirals for influenza in healthy adults: systematic review. Lancet. 2006 Jan 28;367(9507):303-13.
3. Hayden FG Antiviral resistance in influenza viruses--implications for management and pandemic response. N Engl J Med. 2006 Feb 23;354(8):785-8.
4. de Jong MD, Tran TT, Truong HK, Vo MH, Smith GJ, Nguyen VC, Bach VC, Phan TQ, Do QH, Guan Y, Peiris JS, Tran TH, Farrar J. Oseltamivir resistance during treatment of influenza A (H5N1) infection. N Engl J Med. 2005 Dec 22;353(25):2667-72.
5. Beigel JH, Farrar J, Han AM, Hayden FG, Hyer R, de Jong MD, Lochindarat S, Nguyen TK, Nguyen TH, Tran TH, Nicoll A, Touch S, Yuen KY; Writing Committee of the World Health Organization (WHO) Consultation on Human Influenza A/H5.
Avian influenza A (H5N1) infection in humans.
N Engl J Med. 2005 Sep 29;353(13):1374-85
6. Barroso L, Treanor J, Gubareva L, Hayden FG. Efficacy and tolerability of the oral neuraminidase inhibitor peramivir in experimental human influenza: randomized, controlled trials for prophylaxis and treatment. Antivir Ther. 2005;10(8):901-10.
Contemporary Antimicrobial Focus in Critical Illness: MRSA and Fungi
Matthew C. Moran, BS
The University of Toledo College of Pharmacy
Toledo, Ohio, USA
Steven J. Martin, PharmD, FCCM, BCPS
The University of Toledo College of Pharmacy
Toledo, Ohio, USA
1. Wunderink RG, Rello J, Cammarata SK, Croos-Dabrera RV, Kollef MH. Linezolid vs vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia. Chest. 2003;124:1789-97.
2. Kollef MH, Rello J, Cammarata SK, Croos-Dabrera RV, Wunderink RG. Clinical cure and survival in Gram-positive ventilator-associated pneumonia: retrospective analysis of two double-blind studies comparing linezolid with vancomycin. Intensive Care Med. 2004;30:388-94.
3. Weigelt J, Itani K, Stevens D, Lau W, Dryden M, Knirsch C.Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections. Antimicrob Agents Chemother. 2005;49:2260-6.
4. Whitehouse T, Cepeda JA, Shulman R, et al. Pharmacokinetic studies of linezolid and teicoplanin in the critically ill. J Antimicrob Chemother. 2005;55:333-40.
5. Fowler V, Cosgrove S, Abrutyn E, et al. Daptomycin vs. Standard Therapy for Staphylococcus aureus Bacteremia (SAB) and Infective Endocarditis (SAIE). Abstract K-426a, 45th Interscience Conference on Antimicrobials and Chemotherapy, Washington DC, December 2005
6. Arbeit RD, Maki D, Tally FP, Campanaro E, Eisenstein BI. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections.Clin Infect Dis. 2004;38:1673-81.
7. Silverman JA, Mortin LI, Vanpraagh AD, Li T, Alder J. Inhibition of daptomycin by pulmonary surfactant: in vitro modeling and clinical impact. J Infect Dis. 2005;191:2149-52.
8. Breedt J, Teras J, Gardovskis J, et al. Safety and efficacy of tigecycline in treatment of skin and skin structure infections: results of a double-blind phase 3 comparison study with vancomycin-aztreonam. Antimicrob Agents Chemother 2005;49:4658-66.
9. Oliva ME, Rekha A, Yellin A, et al. A multicenter trial of the efficacy and safety of tigecycline versus imipenem/cilastatin in patients with complicated intra-abdominal infections. BMC Infectious Diseases 2005, 5:88 doi:10.1186/1471-2334-5-88
10. Jauregui LE, Babazadeh S, Seltzer E, et al. Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections. Clin Infect Dis. 2005;41:1407-15.
11. ATS and IDSA. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Amer J Resp Crit Care Med 2005;171:388–416.
12. Kullberg BJ, Sobel JD, Ruhnke M, et al.. Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial. Lancet 2005; 366: 1435–42